Pentadecapeptide
Also known as: BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
Key Facts: Pentadecapeptide
- Category
- Healing
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical - Pentadecapeptide BPC-157 is the same compound as BPC-157. FDA removed BPC-157 from Category 2 "do not compound" list effective April 22, 2026. PCAC voted 8-6 to recommend BPC-157 for the 503A authorized compounding bulks list on July 23, 2026. This is a non-binding advisory recommendation; FDA must complete formal notice-and-comment rulemaking (typically 12-24 months) before any legal compounding change takes effect. No FDA approval for any indication.
- Banned in Sport (WADA)
- Prohibited at all times under WADA S0 (non-approved substances), where BPC-157 is named directly.
- Administration
- Subcutaneous injection
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- 4-12 weeks typical
How does Pentadecapeptide work?
BPC-157's proposed mechanism is still a hypothesis built mostly on animal work, not settled biology. The most consistent finding is that it appears to promote angiogenesis, the growth of new blood vessels, partly by upregulating the VEGFR2 (vascular endothelial growth factor receptor 2) pathway, which would help explain faster tissue repair. Researchers have also reported effects on the nitric oxide system and interactions with dopaminergic, serotonergic, and adrenergic signaling in rodents, which is sometimes invoked to explain its claimed gut-brain and mood effects. It does not have one clean, identified receptor the way a hormone does, and the molecular details remain unconfirmed in humans.
What does the research show?
The preclinical record is genuinely large and fairly consistent: across decades of rat and mouse studies, BPC-157 has accelerated healing of tendon, ligament, muscle, bone, and gut tissue, and protected against ulcers and various toxic insults, with one tendon study (Journal of Applied Physiology, 2011) showing it speeds tendon cell outgrowth, survival, and migration. That sounds impressive until you notice the gap between the lab bench and people. Recent reviews, including a 2025 MDPI literature and patent review and a 2025 narrative review in PMC, state plainly that there is no approved formulation, no validated human dose, and no completed Phase II trial. So while the animal data is real and reproducible, the human evidence is effectively zero, and claims about what it does in people are extrapolation, not proof. It is also banned by the World Anti-Doping Agency, which tells you it is treated as a performance drug, not a vetted medicine.
What doses have been studied?
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses similar to BPC-157 protocols
Doses from Studies
250-500 mcg twice daily
Duration
4-12 weeks typical
Administration
Subcutaneous injection
When and how is Pentadecapeptide taken?
Best Time to Take
Morning and evening (or near injury site timing)
1-2 times daily, consistent timing
Food Recommendation
With or without food
Why This Timing?
BPC-157 has systemic healing effects. Split dosing maintains stable levels. Can be timed around activity for injury healing.
What are the side effects of Pentadecapeptide?
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●See BPC-157 (same compound)
- ●Generally well-tolerated
- ●Nausea
- ●Dizziness
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
References
- https://www.mdpi.com/1424-8247/18/2/185
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- https://journals.physiology.org/doi/full/10.1152/japplphysiol.00945.2010
- https://pubmed.ncbi.nlm.nih.gov/9073154/
- https://www.mdpi.com/1999-4923/18/5/625
Research This Peptide Further
Frequently Asked Questions
What does Pentadecapeptide do?
Pentadecapeptide almost always means BPC-157, a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. It is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. There is no FDA approval and no completed human clinical trial proving it does any of this.
How does Pentadecapeptide work?
BPC-157's proposed mechanism is still a hypothesis built mostly on animal work, not settled biology. The most consistent finding is that it appears to promote angiogenesis, the growth of new blood vessels, partly by upregulating the VEGFR2 (vascular endothelial growth factor receptor 2) pathway, which would help explain faster tissue repair. Researchers have also reported effects on the nitric oxide system and interactions with dopaminergic, serotonergic, and adrenergic signaling in rodents, which is sometimes invoked to explain its claimed gut-brain and mood effects. It does not have one clean, identified receptor the way a hormone does, and the molecular details remain unconfirmed in humans.
Is Pentadecapeptide FDA approved?
No, Pentadecapeptide is not currently FDA approved. Current status: Preclinical - Pentadecapeptide BPC-157 is the same compound as BPC-157. FDA removed BPC-157 from Category 2 "do not compound" list effective April 22, 2026. PCAC voted 8-6 to recommend BPC-157 for the 503A authorized compounding bulks list on July 23, 2026. This is a non-binding advisory recommendation; FDA must complete formal notice-and-comment rulemaking (typically 12-24 months) before any legal compounding change takes effect. No FDA approval for any indication.
Is Pentadecapeptide banned in sport?
Prohibited at all times under WADA S0 (non-approved substances), where BPC-157 is named directly.
What are the side effects of Pentadecapeptide?
Reported side effects include: See BPC-157 (same compound), Generally well-tolerated, Nausea, Dizziness, May trigger histamine release - use caution with MCAS or histamine sensitivity. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Pentadecapeptide?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Pentadecapeptide or used in similar applications.
BPC-157
PreclinicalBPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.
HealingTB-500
PreclinicalTB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
HealingB7-33
PreclinicalB7-33 is a 27-amino-acid, single-chain peptide cut down from the B-chain of human relaxin-2, the hormone that loosens tissue during pregnancy. Relaxin itself has strong anti-scarring effects but is a complex two-chain molecule that is hard and expensive to make, so an Australian group (Hossain and colleagues, 2016) designed B7-33 as a simpler version. In rodent models it reduced heart and lung fibrosis about as well as full relaxin. It has never been tested in humans.
HealingZiconotide
FDAZiconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
HealingThymosin Beta-4
Clinical TrialsThymosin beta-4 (Tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. Its main job is binding and sequestering G-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. It is researched heavily for healing of skin, cornea, and heart tissue, but it is not an FDA-approved drug. (The injectable sold as TB-500 is a synthetic fragment marketed as related to Tbeta4, not the full natural peptide.)
HealingDermorphin
PreclinicalDermorphin is a seven-amino-acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first found in the skin of South American Phyllomedusa frogs. It is a strong, highly selective mu-opioid agonist, the same receptor morphine and fentanyl hit, and in mouse brain-injection studies it was hundreds of times more potent than morphine. It is not approved anywhere for human use. Its main claim to fame is doping: it was caught in dozens of American racehorses in 2012, where it was nicknamed 'frog juice'. This is an opioid, and it should be treated like one.
HealingWant updates on Pentadecapeptide research?
Get an email when we add new research here, when it is back in stock, or when the price drops.